Nedaplatin

Toxicity

The toxic effects of nedaplatin are likely similar to those of Cisplatin which produces nausea, vomiting, peripheral neuropathy, and ototoxicity . A major difference between the compounds is the large reduction in nephrotoxicity of nedaplatin compared to Cisplatin .

Description

Nedaplatin, a novel second generation platinum complex, was marketed in Japan for the treatment of a variety of cancers including: head and neck, small-cell and non-small cell lung, oesophageal, prostatic, testicular, ovarian, cervical, bladder, and uterine cancers. Platinum anticancer agents, prototyped by cisplatin, have been reported to be hydrolyzed to the mono- or diaquated species of diamine platinum which react with nucleophilic sites on DNA to cause intrastrand and interstrand crosslinks and DNA-protein crosslinks, which result in cytotoxicity. Nedaplatin was reportedly more active than cisplatin against several solid tumors while sharing less nephro- and gastrointestinal toxicity to cisplatin in viva The minimal renal toxicity displayed by nedaplatin allows its use in patients with deteriorated renal function.

Originator

Shionogi (Japan)

The Uses of Nedaplatin

Nedaplatin is a platinum complex that has potent antineoplatic activity.

The Uses of Nedaplatin

anticancer

Indications

Used in the treatment of non-small cell lung cancer, small cell lung cancer, oesophygeal cancer, and head and neck cancers .

Background

Nedaplatin is a second generation platinum analog . It is less nephrotoxic than Cisplatin but has proven equally effective. It was approved for use in Japan in 1995.

What are the applications of Application

Nedaplatin is a platinum complex that has potent antineoplatic activity

brand name

Aqupla

Pharmaceutical Applications

Nedaplatin, cis-diammineglycolatoplatinum(II), is structurally similar to carboplatin. The chemical structure consists of a central platinum(II) atom with two cis-ammonia groups as nonleaving groups and – in contrast to carboplatin – the dianionic form of glycolic acid as the leaving group. Nedaplatin has been approved for the clinical use in the Japanese market for the treatment of head and neck, testicular, ovarian, lung and cervical cancer. It is typically administered by IV injection and its dose-limiting side effect is myelosuppression.

Pharmacokinetics

Nedaplatin damages DNA and induces cell death in cancer cells . It also functions as a radiosensitizer, increasing the susceptibility of the affected cells to radiation therapy .

Metabolism

Not Available